Ann: AGM Presentation, page-37

By the way, the New England Journal of Medicine (where VX-147 results are published) is no joke.

Your game: 1. you may see a pop (by gullible retail shareholders) at the end of phase 3 results (institutions are seeing through these).
2. In terms of real achievement, maybe they gain traction in Europe (if they reach the end line faster than Vertex, the US is a no-go). By the way, the European company may only sit on Dimerix products (no royalty after that) if they negotiate a reasonable deal with Vertex (if they both succeed). Why to fight a battle with the better product?
Each to their own. While I was embarrassing and stupid (thanks for your nice treatment): I did what I should have done in terms of sharing thoughts.

Good luck to all shareholders.